Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Brainstorm Cell Therapeutics Stock Down 5.0 %

Shares of BCLI traded down $0.10 during trading hours on Monday, hitting $1.89. 77,517 shares of the company were exchanged, compared to its average volume of 104,362. The firm’s fifty day moving average is $1.81 and its 200 day moving average is $3.12. The company has a market cap of $10.77 million, a price-to-earnings ratio of -0.39 and a beta of 0.29. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.